Dr. Serdar Turhal is a highly experienced oncologist specializing in medical oncology and chemotherapy for breast cancer at Anadolu Medical Center. He is a member of many international oncology associations and has authored numerous articles in international publications. He specializes in prognostic factors and the therapy of malignant gastrointestinal neoplasms. To receive a consultation from Dr. Turhal, please submit a request on Bookimed.
Read moreDr. Ahmet Belici is an experienced medical oncologist with 20+ years of experience specializing in sarcoma and lung cancer treatments.
Read moreFields of Study and Interests
Breast Cancer
Lung Cancer
Colon Cancer
Stomach Cancer
Rectum Cancer
Ovarian Cancer
Uterine Cancer
Liver Cancer
Esophageal Cancer - Esophagus Cancer
Kidney Cancer
Larynx Cancer - Throat Cancer
Thyroid Cancer
Head and Neck Cancers
Gynecological Cancers
Pancreatic Cancer
Esophageal Cancer - Esophagus Cancer
Uterine Cancer
Brain Cancers - Brain Tumors
Soft Tissue Cancer - Sarcomas
Prostate Cancer
Bladder Cancer
Bile Duct Cancer
Testicular Cancer
Cervical Cancer
Mouth, Tongue, Lip Cancers
Gastrointestinal System Cancers
Bone Tumors
Trachea and Bronchial Cancers
Skin Cancers - Skin Cancers
Skeletal System Tumors
Gallbladder Cancer
Mesothelioma
Education
Cumhuriyet University Faculty of Medicine, 2004
Istanbul Haydarpaşa Education and Research Hospital Internal Medicine Specialist, 2010
Karadeniz Technical University Faculty of Medicine Medical Oncology Specialist, 2015
Career
MD Andeson Cancer Center, USA, 2008
Sunnybrook Odette Cancer Center Breast Cancer Clinic, Canada, 2017
Moffit Cancer Center, USA 2022
Istanbul Haydarpaşa Education and Research Hospital Internal Medicine, 2010
İdil State Hospital Internal Medicine Clinic, 2011
Karadeniz Technical University Faculty of Medicine Medical Oncology Clinic, 2015
Istanbul Göztepe Education and Research Hospital Medical Oncology Clinic, 2018
Yeniyüzyıl University Gaziosmanpaşa Hospital Medical Oncology Clinic, 2020
Ataşehir Medicana Hospital, Medical Oncology Clinic, 2022
Read moreDoctor's visit | price on request |
CyberKnife for lung cancer | $1641 - $1969 |
Doctor's visit | price on request |
CyberKnife | $8500 - $14000 |
Da Vinci Robotic System | $18000 - $25000 |
Radiotherapy for lung cancer | $12000 - $18000 |
20 top ranked Lung cancer doctors in the world are represented on this page. The list includes only verified specialists known for their experience and high success rates.
The ranking is composed according to the Bookimed patient reviews and considers the rating of hospitals where doctors practice.
Top 5 Lung cancer doctors on Bookimed.com:
The specialist’s CV contains details about the doctor’s expertise and work experience, education, scientific research, and languages spoken. Compare information on several specialists, read carefully about their experience, success rates, and methods they apply. Make sure the chosen doctor has relevant experience in the treatment of a medical issue you are looking for. Read reviews of patients who had a consultation with the chosen specialist.
Famous Lung cancer doctors have vast experience, continue education constantly, participate in professional associations and have positive feedback from patients treated.
The price for the consultation on Lung cancer varies between experts and depends on certain factors, such as:
To schedule your visit, just submit a request on Bookimed.com. Our coordinator will contact you to discuss the time and details of the appointment, so everything will go smoothly.
We can help to find the right doctors for Lung cancer if you have any difficulties with a choice. Bookimed services are free for patients ♥
Medical Oncology
Fields of Study and Interests
Gastrointestinal System (GI) Cancer
Cancer Vaccines
Breast Cancers
Lung Cancer
Rare Cancers
Education
MD: Necmettin Erbakan University Meram Faculty of Medicine, 1994
Internal Medicine Specialist Training: Atatürk University Faculty of Medicine, 2004
Internal Medicine Specialist Training: Kafkas University Faculty of Medicine, 2007
Medical Oncology Sub-Specialist Training: Selçuk University Faculty of Medicine, 2010
Medical Oncology Sub-Specialist Training: Istanbul University Oncology Institute, 2013
Career
Assistant Professor: Atatürk University Faculty of Medicine, 2005
Assist. Prof. Dr.: Kafkas University, 2006-2007
Minor Assistant Professor: Selçuk University – Medical Oncology, 2007-2010
Minor Assistant Professor: Istanbul University Oncology Institute – Medical Oncology,
2012-2013
Specialist Professor: Istanbul University Oncology Institute – Medical Oncology, 2013-2017
Assoc. Prof. Dr.: Istanbul University Oncology Institute – Medical Oncology, 2017-2023
Prof. Dr.: Istanbul University Oncology Institute – Medical Oncology, 2023-present
Read moreDoctor's visit | price on request |
CyberKnife for lung cancer | $1641 - $1969 |
Doctor's visit | price on request |
Immunotherapy with Keytruda (Pembolizumab) | $5800 - $6000 |
Lobectomy | $9600 |
Pneumonectomy | $11200 |
Prof. Hale Başak Çağlar is a radiation oncology director and expert in treating breast, lung, pancreatic, prostate and bone cancer. She is highly qualified, having obtained her education from Gazi University, Marmara University and Medipol University, and is a member of numerous societies, such as the American Society for Therapeutic Radiation Oncology, the European Society for Therapeutic Radiation Oncology, the European Organisation for Research and Treatment of Cancer and the Radiosurgery Society.
Read moreDoctor's visit | price on request |
CyberKnife | $8500 - $14000 |
Da Vinci Robotic System | $18000 - $25000 |
Radiotherapy for lung cancer | $12000 - $18000 |
AREAS OF INTEREST
Education and Specialization
Experience
Professional Memberships
Turkish Society of Medical Oncology
Education and Training:
Areas of Expertise:
Achievements and Awards:
Doctor's visit | price on request |
Brachytherapy | $4800 |
Immunotherapy with Keytruda (Pembolizumab) | $12760 |
Lung cancer surgery | $10700 - $12500 |
Doctor's visit | price on request |
Chemotherapy for lung cancer | $2000 - $9000 |
Lobectomy | $8732.53 - $11539.42 |
Lung cancer surgery | $10300 - $16400 |
Professional Experience
Gayrettepe Florence Nigthingale Hospital
Medical Oncology Department
Besiktas/Istanbul/Turkey (ongoing)
Education:
He became Professor (22/April /2016)
Medical Oncology
Attending Phys.in Gastrointestinal Oncology (January 2005 ,2009)
Istanbul University Oncology Institue,
Department of Medical Oncology
Medical Oncology Fellowship (December 2001-December2004)
Istanbul University, Istanbul Medical Faculty
Hemodialysis Traning (May1996-January1997)
Istanbul University ,bCerrahpasa Medical Faculty
Internal Medicine Residency (November 1991-November 1996)
Istanbul University ,bCerrahpasa Medical Faculty
Ege University Medical Faculty (1985-1991)
Professional Experience
February 1999-November 2001
Metropolitan Florence Nigthingale Hospital
American Cancer Center, Gayrettepe/İstanbul
April1997- October 1998
Bayraktar Dialysis Center
Güngören/ Istanbul
Membership
Turkish Medical Oncology Association
ENET(European Neuroendocrine Tumour Society)
ESMO
ASCO
Read moreEducation
Career
Dr. Duygu Derin is an experienced medical oncologist who specializes in treating gastrointestinal cancers, lung cancer, and gynecologic neoplasms. She is a member of several oncology associations and has published more than 30 national and international scientific papers. She graduated from Galatasaray Medical High School and achieved a Medical Doctor rank from the Medical Faculty of Istanbul University. She has completed internships and professional development courses in various hospitals and holds the title of Associate Professor.
Read moreProf. Sadi Kerem Okutur is a Turkish medical oncologist with over 20 years of experience. He is currently working at Memorial Bahçelievler Hospital, and has held various positions in the past. He has a degree in general medicine, and a residency in internal medicine and medical oncology. Prof. Okutur has won a research award and authored numerous papers and book chapters. He is a member of various medical societies.
Read moreDoctor's visit | price on request |
Chemotherapy for lung cancer | $2000 - $9000 |
Lobectomy | $8732.53 - $11539.42 |
Lung cancer surgery | $10300 - $16400 |
PROFESSIONAL EXPERIENCE
2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine
2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine
06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine
10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship
2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship
2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist
2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.
EDUCATION
2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey
2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey
2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey
2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey
2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.
2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey
INTERNATIONAL CLINICAL TRIALS:
1. Astefania - ROCHE
2. PFİZER
3. RECITE - AMGEN
4. NAVIGATE - BAYER
5. RUBY - Tesaro (PRA)
6. ENGOT-ov43/GOG-3036 - MSD
7. ASTRA ZENECA
8. ROSY-O - ASTRA ZENECA
INTERNATIONAL PUBLICATIONS
I. Published journal articles indexed by SCI, SSCI, and AHCI
Weekly Paclitaxel in Classic Kaposi Sarcoma
Carboplatin Desensitization in Ovarian Carcinoma
High-Dose Chemotherapy for Ewing’s Sarcoma
Multidrug Refractory TFE3(+) Renal Cell Carcinoma
Crizotinib Efficacy in NSCLC with MET Alterations
Clinicopathological Features in ALK Mutant NSCLC
PSMA-Based Tumor Burden in Prostate Cancer
Atezolizumab in Metastatic Urothelial Carcinoma
Pulmonary Sarcomatoid Carcinoma
Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma
Atezolizumab with Chemotherapy in Small Cell Lung Cancer
FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer
Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients
Real-Life Efficacy of Osimertinib in Advanced NSCLC
ALK-Positive Cells Percentage and Alectinib Efficacy
Real-World Data on Alectinib in ALK-Positive NSCLC
Prognostic Factors in Metastatic RCC with T790M Mutation
FLOT Regimen in Metastatic Gastric Cancer
Desensitization Protocol in Lenalidomide Hypersensitivity Reactions
Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity
Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors
Subsequent Treatments in Hormone-Positive Breast Cancer Progression
Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer
Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer
Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer
Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer
Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients
Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients
Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases
FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer
Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer
Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma
Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma
Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)
Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)
Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.
Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49
Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4
Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.
Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology
Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)
Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)
Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)
Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)
Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye
Thesis:
Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)
International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)
Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination
Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study
Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer
Efficacy of temozolomide in pretreated patients with metastatic sarcoma
Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors
Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma
Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases
Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma
Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences
Read more
Doctor's visit | price on request |
Lung segmentectomy | $12000 - $15000 |
Lobectomy | $12000 - $18000 |
Radiotherapy for lung cancer | $4000 - $6000 |